Kura Oncology, Inc. (NASDAQ:KURA) Receives $23.89 Consensus Target Price from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $23.89.

KURA has been the topic of a number of recent analyst reports. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Scotiabank reduced their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. UBS Group lowered their price objective on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research report on Monday, April 28th. Finally, StockNews.com lowered Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd.

Kura Oncology Stock Performance

Shares of KURA stock opened at $5.79 on Friday. The company’s 50 day moving average is $6.67 and its 200 day moving average is $9.42. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $467.70 million, a price-to-earnings ratio of -2.45 and a beta of 0.50. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $23.48.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to analysts’ expectations of $39.08 million. On average, sell-side analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC grew its position in Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after purchasing an additional 84,563 shares during the period. SG Americas Securities LLC acquired a new stake in Kura Oncology during the fourth quarter worth about $436,000. Moody Aldrich Partners LLC raised its position in Kura Oncology by 42.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock valued at $1,251,000 after acquiring an additional 42,712 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after acquiring an additional 2,076 shares during the period. Finally, Jennison Associates LLC purchased a new stake in Kura Oncology in the 4th quarter worth approximately $623,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.